Table 2.
Summary of Mismatch Repair (MMR) Immunoperoxidase Results in Cytology Effusion Specimens and Concordance With Surgical Pathology Specimens
| Case | Cancer Type |
No. of Tumor Cells |
MMR IPOX Cell Block |
MMR IPOX/ MSI-PCR Surgical |
Concordant | |||
|---|---|---|---|---|---|---|---|---|
| MLH1 | PMS2 | MSH2 | MSH6 | |||||
| 1 | CRC | <10 | R | R | R | R | Intact | Yes |
| 2 | CRC | <10 | R | R | R | R | Intact | Yes |
| 3 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 4 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 5 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 6 | EC | 10–50 | R | R | L | L | L MSH2/6 | Yes |
| 7 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 8 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 9 | EC | 10–50 | R | R | R | R | Intact | Yes |
| 10 | CRC | 10–50 | R | R | R | R | Intact | Yes |
| 11 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 12 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 13 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 14 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 15 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 16 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 17 | EC | 51–300 | R | R | R | R | Intact | Yes |
| 18 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 19 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 20 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 21 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 22 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 23 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 24 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 25 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 26 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 27 | CRC | 51–300 | R | R | R | R | Intact | Yes |
| 28 | CRC | >300 | R | R | R | R | Intact | Yes |
| 29 | CRC | >300 | R | R | R | R | Intact | Yes |
| 30 | CRC | >300 | R | R | R | R | Intact | Yes |
| 31 | CRC | >300 | R | R | R | R | Intact | Yes |
| 32 | CRC | >300 | R | R | R | R | Intact | Yes |
| 33 | CRC | >300 | R | R | R | R | Intact | Yes |
| 34 | EC | >300 | R | R | R | R | Intact | Yes |
| 35 | CRC | >300 | R | R | R | R | Intact | Yes |
| 36 | CRC | >300 | R | R | R | R | Intact | Yes |
| 37 | CRC | >300 | R | R | R | R | Intact | Yes |
| 38 | CRC | >300 | R | R | R | R | Intact | Yes |
| 39 | CRC | >300 | R | R | R | R | Intact | Yes |
| 40 | CRC | >300 | R | R | R | R | Intact | Yes |
| 41 | CRC | >300 | R | R | R | R | Intact | Yes |
| 42 | EC | >300 | R | R | R | R | Intact | Yes |
| 43 | EC | >300 | R | R | R | R | Intact | Yes |
| 44 | CRC | >300 | R | R | R | R | Intact | Yes |
| 45 | CRC | >300 | R | R | R | R | Intact | Yes |
| 46 | CRC | 10–50 | R | R | R | S-CIFT | Intact | Inconclusive |
| 47 | EC | 10–50 | S-CIFT | R | R | NC | Intact | Inconclusive |
| 48 | CRC | 10–50 | R | R | R | S-QS | Intact | Inconclusive |
| 49 | CRC | 51–300 | R | R | S-CIFT | L | L MSH2/6 | Inconclusive |
| 50 | CRC | 51–300 | R | R | R | S-CIFT | Intact | Inconclusive |
| 51 | CRC | 51–300 | R | R | R | NC | Intact | Inconclusive |
| 52 | CRC | 51–300 | R | R | R | L | Intact | No |
| 53 | CRC | 51–300 | S-QS | L | R | R | Intact | No |
Abbreviations: CRC, colorectal carcinoma; EC, endometrial carcinoma; IPOX, immunoperoxidase; L, lost; MSI, microsatellite instability; NC, noncontributory; PCR, polymerase chain reaction; R, retained; S-CIFT, suboptimal–focal staining of cells indefinite for tumor; S-QS, suboptimal–tumor with questionable staining.